Status:
COMPLETED
FET-PET Directed Simultaneous In-field Boost for Primary GBM
Lead Sponsor:
Prof. Franciszek Lukaszczyk Memorial Oncology Center
Conditions:
Glioblastoma Multiforme
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The combination of anatomical MRI examination with functional examination of tissue metabolic activity such as FET-PET (PET using the radiotracer - 18F-fluoro-ethyl-tyrosine) is a valuable tool to det...
Detailed Description
In the case of the treatment of glioblastoma multiforme, as a standard, radiotherapy lasts 6 weeks, and the extension of treatment may adversely affect the tumor cells death, the patient's well-being ...
Eligibility Criteria
Inclusion
- Histopathological confirmation of glioblastoma (WHO grade IV)
- Age between 18-75 years of age
- General condition according to the Zubrod scale 0 or 2
- The results of the blood counts are normal
- Liver enzyme parameters normal
- The results of the parameters of the patient's functions are normal
- Informed consent to participate in the category
Exclusion
- Coexistence of another cancer
- The location of the tumor in the area of the brain stem or cerebellum
- Prior brain radiation therapy
- No uptake visible in the FET-PET imaging
- Contraindications for MRI
- Contraindications to radiotherapy or chemotherapy
- Pregnancy, lack of consent to the use of protection against pregnancy, puerperium
- Alcohol addiction
- Mental illness
- Claustrophobia
Key Trial Info
Start Date :
February 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04790097
Start Date
February 21 2017
End Date
December 30 2020
Last Update
May 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Franciszek Lukaszczyk Oncology Center
Bydgoszcz, Poland